Work

Novel therapeutics in metastatic colorectal cancer: molecular insights and pharmacogenomic implications

Year: 2016

Type: article

Abstract: Although the survival of metastatic colorectal cancer (mCRC) patients has improved five-fold over the last century, CRC remains a significant global health burden. Impressive strides have been made in identifying new regimens, employing maintenance strategies to limit treatment toxicities, and combining multidisciplinary approaches to achieve cure in oligometastatic disease. Attempts at personalized integration of targeted agents have been limited by the ability to identify molecularly enriched patient populations most likely to benefit. In this review, we discuss novel therapeutics and regimens recently approved and in development for mCRC. In addition, we discuss using older agents in novel combination and maintenance strategies, and highlight evidence for implementing pharmacogenomic data and non-invasive monitoring into the personalized management of mCRC patients.

Source: Expert Review of Clinical Pharmacology

DOI: 10.1586/17512433.2016.1172961

Authors: Diana L. Hanna, Heinz-Josef Lenz

Institutions: University of Southern California, Hoag Memorial Hospital Presbyterian, USC Norris Comprehensive Cancer Center

Language: English

Topic: Colorectal Cancer Treatments and Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Cancer Institute